

Journal Pre-proof



Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS): An International Multidisciplinary Consensus

Christopher Ma, MD MPH, Alain M. Schoepfer, MD, Ekaterina Safroneeva, PhD, on behalf of the COREOS Collaborators

PII: S0016-5085(21)03020-1
DOI: <https://doi.org/10.1053/j.gastro.2021.04.080>
Reference: YGAST 64352

To appear in: *Gastroenterology*
Accepted Date: 13 April 2021

Please cite this article as: Ma C, Schoepfer AM, Safroneeva E, on behalf of the COREOS Collaborators, Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS): An International Multidisciplinary Consensus, *Gastroenterology* (2021), doi: <https://doi.org/10.1053/j.gastro.2021.04.080>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 by the AGA Institute

1 **Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic**
2 **Esophagitis (COREOS): An International Multidisciplinary Consensus**

3

4 **Authors:**

5 Christopher Ma, MD MPH^{1,2*}, Alain M. Schoepfer, MD^{3*}, and Ekaterina Safroneeva, PhD⁴ on
6 behalf of the COREOS Collaborators

7 * equal contribution

8

9 **Affiliations:**

10 1 Division of Gastroenterology and Hepatology, Departments of Medicine & Community
11 Health Sciences, University of Calgary, Calgary, Alberta, Canada

12 2 Alimentiv Inc, London, Ontario, Canada

13 3 Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois
14 (CHUV) and University of Lausanne, Lausanne, Switzerland

15 4 Institute of Social and Preventive Medicine, University of Bern, Switzerland

16

17 **Short Title:** Development of a Core Outcome Set for EoE

18 **Article Type:** Commentary

19

20 **Word Counts:**

21 Abstract Word Count: N/A

22 Manuscript Word Count: 2635

23 Number of Tables: 1

24 Number of Figures: 1

25

26 **Declaration of funding interests:**

27 Work supported by grants from the Swiss National Science Foundation (32003B_160115/1 to
28 AMS and 185008 to ES)

29

30 **Writing assistance:** None

31 **Keywords:** eosinophilic esophagitis; outcomes; clinical trials; endpoints; histology;
32 histopathology; endoscopy; symptoms; patient reported outcomes; quality of life.

33

34 **Guarantor of the article:** Ekaterina Safroneeva, PhD

35 **Authorship Statement:** All authors have approved the final version of this manuscript.

36 **Acknowledgments:** The COREOS authors would like to acknowledge the following
37 contributors: 1) EUREOS and CEGIR organizations for endorsing the COREOS exercise; 2) the
38 members of CEGIR, EUREOS, and EGID committee of AAAAI for participating in domains
39 round but not in other rounds including Heather Dawson, Marion Groetch, Cord Langner,
40 Sameer Mathur, Stephan Miehke, Melanie Mukhija, Isabel Pérez-Martínez, Caroline Saad,
41 Divya Seth, Hans-Uwe Simon; 3) Leonardo Guizzetti, PhD, employee of Alimentiv Inc., for help
42 with statistical methodology; 4) John MacDonald for assistance with technical editing of the
43 manuscript; and 5) patients participating in the study for informing the content of this exercise.

44

45 **Correspondence address:**

46 Ekaterina Safroneeva, PhD

47 Institute of Social and Preventive Medicine, University of Bern

48 Mittelstrasse 43, Bern 3012, Switzerland

49 Email: ekaterina.safroneeva@ispm.unibe.ch

50 **Version:** April 11, 2021

51 **THE COREOS COLLABORATORS**

52

53 **Authors:**

54 Christopher Ma, MD MPH^{1,2*}, Alain M. Schoepfer, MD^{3*}, Evan S. Dellon, MD, MPH⁴, Albert J.
55 Bredenoord, MD, PhD⁵, Mirna Chehade, MD, MPH⁶, Margaret H. Collins, MD⁷, Brian G.
56 Feagan, MD^{2,8,9}, Glenn T. Furuta, MD¹⁰, Sandeep K. Gupta, MD¹¹, Ikuo Hirano, MD¹², Vipul
57 Jairath, MD PhD^{2,8,9}, David A. Katzka, MD¹³, Rish K. Pai, MD, PhD¹⁴, Marc E. Rothenberg, MD,
58 PhD¹⁵, Alex Straumann, MD¹⁶, Seema S. Aceves, MD, PhD¹⁷, Jeffrey A. Alexander, MD¹³,
59 Nicoleta C. Arva, MD¹⁸, Dan Atkins, MD¹⁹, Luc Biedermann, MD¹⁶, Carine Blanchard, PhD²⁰,
60 Antonella Cianferoni, MD, PhD²¹, Constanza Ciriza de los Rios, MD²², Frederic Clayton, MD²³,
61 Carla M. Davis, MD²⁴, Nicola de Bortoli, MD²⁵, Jorge A. Dias, MD²⁶, Gary W. Falk, MD, MS²⁷,
62 Robert M. Genta, MD^{28,29}, Gisoo Ghaffari, MD³⁰, Nirmala Gonsalves, MD¹², Thomas Greuter,
63 MD^{3,16}, Russell Hopp, DO³¹, Karen S. Hsu Blatman, MD³², Elizabeth T. Jensen, MPH, PhD³³,
64 Doug Johnston, MD³⁴, Amir F. Kagalwalla, MD^{35,36}, Helen M. Larsson, MD, PhD³⁷, John Leung,
65 MD, PhD³⁸, Hubert Louis, MD³⁹, Joanne C. Masterson, PhD⁴⁰, Calies Menard-Katcher, MD¹⁰,
66 Paul A. Menard-Katcher, MD⁴¹, Fouad J. Moawad, MD⁴², Amanda B. Muir, MD⁴³, Vincent A.
67 Mukkada, MD⁴⁴, Roberto Penagini, MD^{45,46}, Robert D. Pesek, MD⁴⁷, Kathryn Peterson, MD⁴⁸,
68 Philip E. Putnam, MD⁴⁴, Alberto Ravelli, MD⁴⁹, Edoardo V. Savarino, MD, PhD⁵⁰, Christoph
69 Schlag, MD, PhD⁵¹, Philipp Schreiner, MD¹⁶, Dagmar Simon, MD⁵², Thomas C. Smyrk, MD⁵³,
70 Jonathan M. Spergel, MD, PhD²¹, Tiffany H. Taft, PsyD¹², Ingrid Terreehorst, MD, PhD⁵⁴, Tim
71 Vanuytsel, MD^{55,56}, Carina Venter, PhD, RD¹⁹, Mario C. Vieira, MD, PhD⁵⁷, Michael Vieth, MD⁵⁸,
72 Berber Vlieg-Boerstra, MD⁵⁹, Ulrike von Arnim, MD⁶⁰, Marjorie M. Walker, BMBS, FRCPath⁶¹,
73 Joshua B. Wechsler, MD, MS³⁵, Philip Woodland, MD⁶², John T. Woosley, MD⁶³, Guang-Yu
74 Yang, MD, PhD⁶⁴, Noam Zevit, MD^{65,66}, and Ekaterina Safroneeva, PhD⁶⁷

75 * equal contribution of two first authors

76

77 **Affiliations:**

- 78 1 Division of Gastroenterology and Hepatology, Departments of Medicine & Community
79 Health Sciences, University of Calgary, Calgary, Alberta, Canada
- 80 2 Alimentiv Inc, London, Ontario, Canada
- 81 3 Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois
82 (CHUV) and University of Lausanne, Lausanne, Switzerland
- 83 4 Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and
84 Hepatology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill,
85 NC, USA
- 86 5 Department of Gastroenterology and Hepatology, Amsterdam University Medical Center,
87 Amsterdam, The Netherlands
- 88 6 Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai,
89 New York, NY, USA
- 90 7 Division of Pathology and Laboratory Medicine, Cincinnati Children's Hospital Medical
91 Center, Cincinnati, OH, USA
- 92 8 Department of Medicine, Western University, London, Ontario, Canada
- 93 9 Department of Epidemiology and Biostatistics, Western University, London, Ontario,
94 Canada
- 95 10 Digestive Health Institute, Children's Hospital Colorado, Gastrointestinal Eosinophilic
96 Diseases Program, Section of Pediatric Gastroenterology, Hepatology and Nutrition,
97 University of Colorado School of Medicine, Aurora, CO, USA
- 98 11 Division of Pediatric Gastroenterology, Hepatology and Nutrition, Riley Hospital for
99 Children/Indiana University School of Medicine, Indianapolis, IN, USA
- 100 12 Division of Gastroenterology & Hepatology, Northwestern University, Feinberg School of
101 Medicine, Chicago, IL, USA
- 102 13 Division of Gastroenterology, Mayo Clinic, Rochester, MN, USA

- 103 14 Department of Pathology and Laboratory Medicine, Mayo Clinic Arizona, Scottsdale, AZ,
104 USA
- 105 15 Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's
106 Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH,
107 USA
- 108 16 Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich,
109 Switzerland
- 110 17 Division of Allergy Immunology, University of California, San Diego, Rady Children's
111 Hospital, San Diego, CA, USA
- 112 18 Department of Pathology and Laboratory Medicine, Ann & Robert H. Lurie Children's
113 Hospital of Chicago, Northwestern University, Feinberg School of Medicine, Chicago, IL,
114 USA
- 115 19 Gastrointestinal Eosinophilic Diseases Program, Children's Hospital of Colorado, Section
116 of Allergy and Immunology, University of Colorado School of Medicine, Aurora, CO, USA
- 117 20 Nestlé Institute of Health Sciences, Nestlé Research, Société des Produits Nestlé, Vevey,
118 Switzerland
- 119 21 Division of Allergy and Immunology, Department of Pediatrics, Children's Hospital of
120 Philadelphia, Perelman School of Medicine at University of Pennsylvania, Philadelphia,
121 PA, USA
- 122 22 Department of Gastroenterology, Hospital Clínico San Carlos, Universidad Complutense,
123 Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
- 124 23 Department of Pathology, The University of Utah, Huntsman Cancer Hospital, Salt Lake
125 City, UT, USA
- 126 24 Immunology, Allergy, and Retrovirology Section of the Department of Pediatrics, Baylor
127 College of Medicine, Texas Children's Hospital, Houston, Texas, USA

- 128 25 Department of Translational Research and New Technology in Medicine and Surgery,
129 Division of Gastroenterology, University of Pisa, Cisanello Hospital, Pisa, Italy
- 130 26 Pediatric Gastroenterology, Centro Hospitalar S. João, Porto, Portugal
- 131 27 Division of Gastroenterology, University of Pennsylvania Perelman School of Medicine,
132 Philadelphia, Pennsylvania, USA
- 133 28 Inform Diagnostics, Irving, TX, USA
- 134 29 Department of Pathology, Baylor College of Medicine, Houston, TX, USA
- 135 30 Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine,
136 Pennsylvania State College of Medicine, Hershey, PA, USA
- 137 31 University of Nebraska Medical Center, Children's Hospital and Medical Center, Omaha,
138 NE, USA
- 139 32 Section of Allergy and Clinical Immunology, Dartmouth-Hitchcock Medical Center,
140 Dartmouth Geisel School of Medicine, Hanover, NH, USA
- 141 33 Wake Forest University School of Medicine, Department of Epidemiology and Prevention,
142 Winston-Salem, NC, United States
- 143 34 Asthma and Allergy Specialists, Charlotte, NC, USA
- 144 35 Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Ann &
145 Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA
- 146 36 Division of Gastroenterology, Department of Pediatrics, John H. Stroger, Jr. Hospital of
147 Cook County, Chicago, IL, USA
- 148 37 Department of ENT, Head and Neck Surgery, NÄL Medical Centre, Trollhättan, Sweden
- 149 38 Division of Gastroenterology, Tufts Medical Center, Boston, MA, USA
- 150 39 Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme
151 Hospital, Université Libre de Bruxelles, Brussels, Belgium
- 152 40 Department of Biology, Maynooth University, Kildare, Ireland

- 153 41 Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical
154 Campus, Aurora, CO, USA
- 155 42 Division of Gastroenterology & Hepatology, Scripps Clinic, La Jolla, CA, USA
- 156 43 Center for Pediatric Eosinophilic Diseases, Division of Gastroenterology and Hepatology &
157 Nutrition, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School
158 of Medicine, Philadelphia, PA, USA
- 159 44 Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital
160 Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine,
161 Cincinnati, OH, USA
- 162 45 Department of Pathophysiology and Transplantation, University of Milano, Milano, Italy
- 163 46 Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy
- 164 47 Division of Allergy and Immunology, University of Arkansas for Medical Sciences and
165 Arkansas Children's Hospital, Little Rock, AR, USA
- 166 48 Division of Gastroenterology, The University of Utah, Salt Lake City, UT, USA
- 167 49 University Department of Pediatrics, Children's Hospital - Spedali Civili, Brescia, Italy
- 168 50 Department of Surgery, Oncology and Gastroenterology, DiSCOG, University of Padua,
169 Padua, Italy
- 170 51 II. Medizinische Klinik, Klinikum Rechts der Isar, Technische Universität München,
171 München, Germany
- 172 52 Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern,
173 Switzerland
- 174 53 Department of Pathology, Mayo Clinic, Rochester, MN, USA
- 175 54 Department of ENT, Amsterdam University Medical Centre, Amsterdam, the Netherlands
- 176 55 Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium
- 177 56 Translational Research in Gastrointestinal Disorders, KU Leuven, Leuven, Belgium

- 178 57 Department of Pediatrics, Pontifical Catholic University of Paraná and Center for Pediatric
179 Gastroenterology, Hospital Pequeno Príncipe, Curitiba, Brazil
- 180 58 Institute for Pathology, Klinikum Bayreuth, Friedrich-Alexander-University Erlangen-
181 Nuremberg, Erlangen, Germany
- 182 59 University Medical Center Groningen University of Groningen, Groningen, The
183 Netherlands
- 184 60 Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital,
185 Magdeburg, Germany
- 186 61 Centre of Research Excellence in Digestive Health, University of Newcastle, NSW
187 Australia
- 188 62 Wingate Institute of Neurogastroenterology, Barts and the London School of Medicine and
189 Dentistry, Queen Mary University of London, London, UK
- 190 63 Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel
191 Hill School of Medicine, Chapel Hill, NC, United States
- 192 64 Division of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, IL,
193 USA
- 194 65 Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical
195 Center of Israel, Petach Tikva, Israel
- 196 66 Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel
- 197 67 Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

198 **FINANCIAL DISCLOSURES**199 **Authors' declaration of personal interests:**

200 C. Ma has (i) received consulting fees from AVIR Pharma Inc. and Alimentiv (formerly Robarts
201 Clinical Trials Inc.); A. M. Schoepfer received (i) consulting fees and/or speaker fees and/or
202 research grants from Adare Pharmaceuticals, Inc., AstraZeneca, AG, Switzerland, Aptalis
203 Pharma, Inc., Celgene Corp., Dr. Falk Pharma, GmbH, Germany, Glaxo Smith Kline, AG, Nestlé
204 S. A., Switzerland, Novartis, AG, Switzerland, Receptos, Inc., and Regeneron Pharmaceuticals,
205 Inc.; E. S. Dellon (i) received research funding from: Adare/Ellodi, Allakos, AstraZeneca, GSK,
206 Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Shire/Takeda; consulting fees
207 from: Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi,
208 Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, GSK, Gossamer Bio, Parexel,
209 Regeneron, Alimentiv Inc., Salix, Sanofi, Shire/Takeda; and educational grants from: Allakos,
210 Banner, Holoclara; A. J. Bredenoord (i) received research funding from Nutricia, Norgine, SST
211 and Bayer and received speaker and/or consulting fees from Laborie, Arena, EsoCap,
212 Medtronic, Dr. Falk Pharma, Calypso Biotech, Gossamer, Alimentiv, Reckett Benkiser,
213 Regeneron and AstraZeneca; M. Chehade received (i) research funding from Regeneron,
214 Allakos, Shire, AstraZeneca, Danone; consulting fees from Regeneron, Allakos, Adare,
215 Shire/Takeda, AstraZeneca, Sanofi, Bristol Myers Squibb; lecture honoraria from Nutricia,
216 Medscape, Vindico; M. H. Collins is (i) a consultant for Allakos, Arena, Astra Zeneca, Calypso,
217 Esocap, GSK, Receptos/BMS, Regeneron, Shire, a Takeda company, and Alimentiv (formerly
218 Robarts Clinical Trials, Inc); and reports research grants from Receptos/BMS, Regeneron, and
219 Shire, a Takeda Company; B. G. Feagan reports (i) consulting fees from Allakos, Alimentiv Inc.
220 (formerly Robarts Clinical Trials, Inc.), Sanofi, Bristol Myers Squibb; G. T. Furuta reports (i)
221 salary support from EnteroTrack; S. K. Gupta reports (i) personal fees from Allakos, Abbott,
222 Adare, Celgene, Gossamer Bio, QOL, Medscape, Viaskin, research grants from Shire, and
223 royalties from UpToDate; I. Hirano reports (i) research funding from: Adare, Allakos, GSK,

224 Meritage, Celgene/Receptos, Regeneron, Shire/Takeda; consulting fees from: Adare, Allakos,
225 Arena, AstraZeneca, Celgene/Receptos, Eli Lilly, EsoCap, GSK, Gossamer Bio, Regeneron,
226 Shire/Takeda; V. Jairath reports (i) consulting fees from Alimentiv Inc. (formerly Robarts
227 Clinical Trials, Inc.); D. A. Katzka reports (i) consulting fees from Takeda, Sanofi, and Shire; R.
228 K. Pai reports consulting fees from Eli Lilly, Genentech, Allergan, and Alimentiv (formerly
229 Robarts Clinical Trials, Inc.); M. E. Rothenberg reports (i) personal fees from Celgene, Astra
230 Zeneca, Arena Pharmaceuticals, Adare Pharmaceuticals, GlaxoSmith Kline, Guidepoint and
231 Suvretta Capital Management, and (ii) has an equity interest in Pulm One, Spoon Guru,
232 ClostraBio, Serpin Pharm and Allakos, and royalties from reslizumab (Teva Pharmaceuticals),
233 PEESV2 (Mapi Research Trust) and UpToDate. M.E.R. is (iii) an inventor of patents owned by
234 Cincinnati Children's Hospital; A. Straumann reports (i) personal fees from Allakos, Astra-
235 Zeneca, Calypso, EsoCap, Falk Pharma, Gossamer, Nutricia, Pfizer, Receptos-Celgene,
236 Regeneron-Sanofi, Roche-Genentec, Shire, Tillotts; S. S. Aceves reports (i) being a consultant
237 for Regeneron, Astra-Zeneca, Astellos, and Alimmune and (iv) a UCSD patent licensed to Shire-
238 Takeda Pharma; J. A. Alexander reports (i) personal fees or grants from Regeneron and Adare
239 Pharmaceuticals and (ii) has equity interest in Meritage Pharmacia; L. Biedermann reports (i)
240 personal fees from Vifor, Falk Pharma, Escap, Calypso; C. Blanchard (ii) is an employee of
241 Société des produits Nestlé S.A.; C. Ciriza de los Rios reports (i) consulting fees for Norgine
242 and Allergan; C. M. Davis reports (i) research grants from the National Institutes of
243 Health/National Institute of Allergy and Infectious Disease (Consortium of Food Allergy
244 Research/Consortium of Eosinophilic Gastrointestinal researchers), DBV Technologies,
245 Aimmune Therapeutics, Regeneron Pharmaceuticals, and owns stock in Moonlight
246 Therapeutics.; G. W. Falk reports (i) grants and/or personal fees from Allakos, Shire/Takeda,
247 ADARE/Ellodi, Regeneron, and Bristol Myers Squibb; R. M. Genta reports (i) consulting fees
248 from Allakos, Adare/Ellodi, and RedHill Pharma; N. Gonsalves receives (i) consulting fees from
249 Allakos, Astra-Zeneca, Nutricia, and Sanofi/Regeneron and royalties from UpToDate; T. Greuter

250 reports (i) consulting contracts with Falk Pharma GmbH and Sanofi-Aventis, and research grant
251 from Novartis; K. S. Hsu Blatman (i) received research funding from Shire/Takeda; H. M.
252 Larsson reports (i) consulting fees from EsoCap Biotech AG; F. J. Moawad reports (i) personal
253 fees from Takeda and Salix; V. A. Mukkada reports (i) grants and/or personal fees from Shire
254 Pharmaceutical; K. Peterson reports (i) personal fees from Alladapt, Eli Lilly, Medscape, Ellodi,
255 Takeda, Allakos, AstraZeneca, Regeneron-Sanofi and research funding from Research
256 support:Astra Zeneca, Ellodi, Regeneron-Sanofi, Allakos, Chobani, and owes (iii) stock from
257 Nexeos; C. Schlag reports (i) consulting fees and/or speaker fees and/or research grants from
258 Adare Pharmaceuticals, Inc., AstraZeneca, Calypso, EsoCap, Dr. Falk Pharma, GmbH,
259 Regeneron Pharmaceuticals, Inc.; P. Schreiner reports (i) consulting fees from Pfizer, Takeda
260 and Janssen-Cilag; J. M. Spergel reports (i) grants and/or personal fees from DBV
261 Technologies, End Allergy Together, Food Allergy Research Education, Aimmune Therapeutics,
262 UpToDate, Regeneron, and Shire; T. H. Taft reports (i) speaking fees from Abbvie, consulting
263 fees from Healthline; T. Vanuytsel (i) has served as a speaker for Abbott, Dr. Falk Pharma,
264 Fresenius Kabi, Kyowa Kirin and Menarini, Takeda and Will Pharma; has served as a consultant
265 and advisory board member for Baxter, Dr. Falk Pharma, Takeda, Tramedico, Truvion,
266 VectivBio and Zealand Pharma; and has received research funding from Danone and MyHealth;
267 C. Venter (i) has provided and reviewed educational material for Danone, Reckitt Benckiser,
268 Abbott Nutrition, DBV technologies, and Nestle Nutrition Institute and received research grants
269 from the National Peanut Board and Reckitt Benckiser; M. C. Vieira reports (i) speaker's fees
270 from Danone Nutricia, and Nestlé S.A; M. Vieth reports (i) speakers fees from Dr Falk Pharma,
271 Shire and Menarini; B. Vlieg-Boerstra; U. von Arnim reports (i) consulting fees from ESOCAP,
272 Abbvie, M SD, Takeda, Falk Pharma; J. B. Wechsler receives (i) consulting fees from Allakos
273 and Regeneron; N. Zevit reports (i) speakers fees for Dr. Falk Pharma and as an advisory board
274 member for Adare Pharmaceuticals; E. Safroneeva (i) received consulting fees from AVIR
275 Pharma Inc., Aptalis Pharma, Inc., Celgene Corp., Novartis, AG, and Regeneron

276 Pharmaceuticals Inc. The rest of the authors declare that they have no relevant conflicts of
277 interest.

Journal Pre-proof

278 **COMMENTARY**

279 **The Need to Define Consensus Outcomes in Eosinophilic Esophagitis**

280 There has been tremendous interest in developing eosinophilic esophagitis (EoE)-specific
281 pharmacotherapies,¹ and over 50 active or enrolling interventional studies are currently
282 registered on Clinicaltrials.gov. Recent positive results from phase III trials of dupilumab, a
283 monoclonal antibody targeting the IL-4 receptor alpha, budesonide orodispersible tablets as
284 both induction and maintenance therapy, and budesonide oral suspension, have inspired even
285 greater enthusiasm for drug development in this field.²⁻⁵ Despite these breakthroughs, efficient
286 drug development in EoE has been hampered by the lack of standardized outcome measures
287 that can be used in both registrational trials to support labelling claims and in observational
288 studies to answer practice-based questions. Agreement on the most appropriate endpoints for
289 use in clinical studies has not been reached, and significant heterogeneity exists in the outcome
290 measures that are reported.⁶ Given the lack of consensus and the increasing scrutiny of
291 outcome measures in clinical trials of EoE, developing a core outcome set (COS) is a research
292 priority. A COS is a consensus-derived minimum set of outcomes that should be measured and
293 reported in all trials in a given therapeutic area.⁷ Using a COS to inform study design and
294 choose endpoints can improve the efficiency of clinical studies by ensuring appropriate
295 outcomes are measured, minimize heterogeneity in reporting, reduce the risk of publication
296 bias, and improve the quality of evidence synthesis by facilitating fair comparisons across
297 different therapies.

298

299 Therefore, in collaboration with the Consortium of Eosinophilic Gastrointestinal Disease
300 Researchers (CEGIR), the European Eosinophilic Esophagitis Research Network (EUREOS),
301 and the Eosinophil Gastrointestinal Disorders (EGID) Committee of The American Academy of
302 Allergy, Asthma, and Immunology (AAAAI), we developed an international consensus COS for

303 use in studies of pharmacologic and dietary interventions for adult and pediatric patients with
304 EoE (COREOS).

305

306 **Methods for Defining the COS**

307 Detailed methods used to define the COS are summarized in the accompanying Meeting
308 Summary. We used a multiple phase approach, conducted in accordance with
309 recommendations from the Core Outcome Measures in Effectiveness Trials (COMET) initiative⁷,
310 ⁸ to identify relevant outcome domains and endpoint definitions for randomized controlled trials
311 (RCTs) and observational studies in adult and pediatric patients with EoE. First, a series of
312 systematic reviews^{6, 9} and patient engagement surveys¹⁰ were conducted to identify candidate
313 outcomes of importance. Input was gathered from a diverse range of patients with EoE to
314 determine their values on the importance of different outcomes and recruited using purposive
315 sampling from multiple clinics to capture a range of disease duration, disease activity, and
316 treatment experiences. A total of 36 patients with EoE participated in semi-structured interviews
317 and 109 patients with EoE completed a paper-based survey. Outcomes identified in the patient
318 engagement surveys and through systematic literature reviewer were organized into eleven
319 domains, and a series of working group meetings were held to review the pertinent endpoints.
320 These domains were then discussed in a moderated face-to-face meeting at Digestive Disease
321 Week 2019 (San Diego, United States) and a Delphi panel of multidisciplinary experts voted to
322 categorize these into core, important, and research agenda domains based on the Outcome
323 Measures in Rheumatology (OMERACT) model.¹¹ In phase 3, a comprehensive list of outcome
324 measures within each core domain was evaluated in a two-round Delphi survey to establish
325 consensus. Finally, a virtual ratification meeting was held to vote on the final outcomes included
326 in the COS.

327

328 The COS panel included diverse stakeholders, reflecting a broad range of clinical knowledge
329 and geographical diversity, including patients with EoE, gastroenterologists, pathologists,
330 allergists, dieticians, psychologists, researchers, and methodologists. Several rounds of Delphi
331 surveys were completed to first rank each domain and subsequently individual outcomes on a
332 9-point Likert scale.¹² Scores of 1-3 indicate an outcome domain that was not considered
333 important for inclusion, scores of 4-6 indicate an outcome domain that was considered important
334 but not critical for inclusion, and scores of 7-9 indicate an outcome domain felt critical for
335 inclusion in the COS. Outcome domains and outcome definitions scored in the 7-9 range by
336 $\geq 70\%$ of panelists and in the 1-3 range by $< 15\%$ of panelists were considered to have met
337 consensus. A moderated video conference to ratify the final COS was conducted December 8,
338 2020. Although this was initially planned as a face-to-face meeting, this was amended to a
339 virtual conference due to COVID-19 public health restrictions. After discussion, panelists
340 anonymously voted on the final items as “Include in the COS”, “Do not include in the COS”, or
341 “Unsure”. Items receiving $\geq 70\%$ of votes in the “Include in the COS” category and $< 15\%$ of votes
342 in the “Do not include in the COS” category were ratified for final inclusion.

343

344 **A COS for EoE**

345 Four outcome domains were voted as critical for inclusion in an EoE COS: *histopathology*,
346 *endoscopy*, *patient-reported symptoms*, and *EoE-specific quality of life (QoL)* (**Figure 1**). While
347 endpoints such as genetic profiling, biomarkers, esophageal distensibility, patient perceptions of
348 health, and immunologic endpoints were important, they were not deemed critical for
349 assessment in every study at this time. Patients with EoE identified improvement in EoE-related
350 symptoms and QoL as the most important outcome domains: $> 90\%$ of patients identified
351 improvements in these domains as important in both the short and long-term. From the four
352 core domains, a total of 122 outcome definitions were identified. Over two rounds of Delphi
353 survey voting by 69 (Round 1) and 62 (Round 2) panelists, a total of 59 outcomes were

354 considered for inclusion (18 for histology, 12 for endoscopy, 19 for patient-reported symptoms,
355 and 10 for EoE-specific QoL). At the ratification meeting, 42 items were discussed and voted on
356 with 33 items included in the final COS. These are summarized in **Table 1**.

357

358 **COS: Histopathology Outcomes**

359 There was consensus that the peak eosinophil count (PEC) should be reported in all RCTs and
360 observational studies, expressed either as eosinophils (eos) per high power field (hpf) (including
361 exact area used and the hpf size reported in mm^2) or as eos per mm^2 , viewed at 400 \times
362 magnification. Several panelists identified that both measures should be reported, as eos/hpf
363 has been historically used, whereas eos per mm^2 adjusts for differences in microscope ocular
364 field size. In RCTs, the EoE Histology Scoring System (EoEHSS)¹³ should be used, and both
365 the grade and stage of each component item reported. There was consensus that histologic
366 remission should be reported in all studies, although the precise threshold for histologic
367 remission was debated. The proportion of patients with < 15 eos/hpf in all esophageal locations
368 should be reported, but there was disagreement on reporting a more stringent threshold of ≤ 6
369 eos/hpf.

370

371 *Implications and Future Directions:* Given the importance of eosinophilic inflammation in
372 defining EoE, histopathology was almost universally agreed upon as a core domain. However,
373 three areas of controversy garnered discussion. First, although using eos/ mm^2 was felt to be
374 advantageous for standardizing density measurements across different microscopes and field
375 sizes,¹⁴ most of the literature to date has expressed the PEC per hpf. There was consensus that
376 this should continue to be reported to facilitate historical treatment comparisons although we
377 advocate for a greater emphasis on reporting eos/ mm^2 (using remission definitions of PEC ≤ 25
378 eos/ mm^2 and < 60 eos/ mm^2 , corresponding to PEC of ≤ 6 eos/hpf and < 15 eos/hpf, respectively).
379 Second, there was consensus that a PEC of < 15 eos/hpf should be used as the threshold to

380 define histologic remission, although this is discordant from recent recommendations from the
381 United States Food and Drug Administration (US FDA).¹⁵ Multiple guidelines have established
382 ≥ 15 eos/hpf as the cutoff for diagnostic purposes, and the panel voted that the proportion of
383 patients achieving a PEC lower than this threshold should continue to be reported.¹⁶⁻¹⁸ A
384 threshold of ≤ 6 eos/hpf may be too stringent to achieve and may not necessarily be appropriate
385 for potential future drug targets with mechanisms of action that do not directly inhibit
386 eosinophils. Nevertheless, we anticipate that in future trials designed for regulatory approval of
387 medications, the proportion of patients with post-treatment PEC < 15 eos/hpf and ≤ 6 eos/hpf will
388 both be reported. Finally, the EoEHSS has been previously demonstrated to be valid, reliable,
389 responsive, applicable in adult and pediatric populations, and measures histologic items that are
390 prevalent in patients with EoE beyond the PEC alone.^{13, 19, 20} For these reasons, panelists felt
391 strongly that the EoEHSS should be routinely evaluated in RCTs. However, the EoEHSS was
392 not included as a core outcome in observational studies due to concerns about the time
393 required for interpretation and lack of an atlas to help pathologists not specialized in EoE to
394 score some of the features, although uptake in clinical practice may increase as it is adopted in
395 RCTs.

396

397 **COS: Endoscopic Outcomes**

398 The panel voted that the EoE Endoscopic Reference Score (EREFS) should be used in both
399 RCTs and observational studies to standardize endoscopic assessment of EoE disease activity,
400 scoring the most severe grade of EoE-associated features. Additionally, both inflammatory and
401 fibrotic components of the EREFS should be reported. Different versions of the EREFS were
402 explored (scoring from 0-8, 0-9, 0-16, and 0-18 with alternative definitions or weighting of the
403 EREFS components). There was consensus to score the major features of the EREFS from 0-8
404 with furrows assessed as absent/present; however, there was extensive discussion that scoring
405 from 0-8 may result in a narrower dynamic range of the EREFS score and decrease

406 responsiveness measured by endoscopy, when compared to scoring the furrows ordinally using
407 grade 0 (absent), grade 1 (mild, vertical lines without visible depth), and grade 2 (severe,
408 vertical lines with mucosal depth/indentation). Additionally, if scoring is performed on a 0-9
409 scale, *post-hoc* analysis collapsing the categories for moderate-to-severe furrows can generate
410 an EREFS score on a 0-8 scale, but not vice versa. For both RCTs and observational studies,
411 there was consensus that endoscopic remission should be defined using an EREFS ≤ 2 .

412
413 *Implications and Future Directions:* The EREFS score has been shown to accurately identify
414 disease activity in both adult and pediatric populations, can be reliably scored by experts and
415 quickly learned by non-experts, and is responsive to treatment.²¹⁻²³ From this consensus, we
416 recommend scoring the EREFS in all EoE RCTs and observational studies, reporting individual
417 component items, and using a cutoff of ≤ 2 for endoscopic remission. However, there was
418 debate as to whether the EREFS should be scored on a 0-9 or 0-8 scale, recognizing that
419 scoring on a broader range may improve the sensitivity of the instrument for detecting change in
420 an RCT setting and can be converted to a 0-8 scale *post-hoc* if required. Functionally, reporting
421 individual component subscores of the EREFS is also required to discern endoscopic
422 inflammatory versus fibrostenotic disease activity. Investigators may choose to grade furrows on
423 a 3-point rather than binary scale and collapse in post-hoc analyses if required.

424

425 **COS: Patient-Reported Symptoms and Quality of Life**

426 There was consensus that validated instruments for patient-reported symptoms, including the
427 Dysphagia Symptoms Questionnaire (DSQ) and the symptom-based EoE Activity Index (EEsAI)
428 with 7-day recall period, should be assessed in EoE RCTs. There was discussion that guidance
429 from the US FDA highlights the use of clinical outcome assessment instruments that use daily
430 evaluations. The EEsAI was developed and has been used in previous RCTs with a 7-day recall
431 period as secondary endpoint, and this outcome was voted to be included in the COS.

432

433 The DSQ was the only 24-hour recall instrument selected out of a myriad of options and is the
434 first such instrument to be validated for use in RCTs, allowing assessment of endpoints such as
435 dysphagia-free days. Other instruments, including both conceptually similar and dissimilar tools,
436 such as the Dysphagia Symptom Diary and Numeric Rating Scales for Dysphagia and Pain,
437 respectively, have been used in other drug development programs, as historically licensing DSQ
438 to all interested parties has not been possible. Given the multitude of instruments with daily
439 recall currently used in RCTs, EEsAI 7-day recall period may be used as secondary endpoint to
440 allow for cross-comparisons between existing instruments.

441

442 There was also consensus that the language used to query dysphagia in adults with EoE
443 include trouble swallowing and delayed/slow passage of food. "Food being stuck" did not reach
444 consensus thresholds in the ratification round. No instruments for measuring symptom severity
445 reached consensus for use in observational studies. Separate instruments were considered for
446 pediatric patients. In pediatric trials, there was consensus that symptoms should be measured
447 using the Pediatric Eosinophilic Esophagitis Symptom Score (PEESS v2.0) for RCTs, but not for
448 observational studies.

449

450 There was consensus that QoL should be measured in EoE RCTs using the EoE-specific QoL
451 questionnaire (EoE-QOL-A) for adults and the Pediatric Quality of Life Inventory (PedsQL) EoE
452 Module for pediatrics. When using the PedsQL EoE Module, it was considered appropriate for
453 both parent-proxy report and child self-report to be reported in RCTs. The panel concluded that
454 disease specific QoL measures rather than generic QoL measures should be chosen for this
455 domain. No instruments for use in all observational studies met the consensus threshold for
456 inclusion in the COS.

457

458 *Implications and Future Directions:* The development of a generic daily recall instrument was
459 identified as a priority, as existing tools such as DSQ and episode-based instruments may be
460 difficult or expensive to implement outside of industry-sponsored RCTs. Whether such
461 instruments should use broad language to describe dysphagia is another relevant consideration,
462 because most available instruments do not assess all possible symptoms relevant for adults
463 with EoE or do not include the most common language used by patients to describe
464 dysphagia.^{24, 25} “Food being stuck” narrowly missed the consensus criteria during ratification
465 round because there were concerns raised that this more accurately reflected food bolus
466 impaction rather than dysphagia, although no clear distinction between language used to
467 describe short- and long-lasting episodes of dysphagia has been noted in qualitative work.
468 Lastly, data on cross comparisons of instruments are scarce, and it is not clear whether
469 assessing symptoms more broadly by including all possible dysphagia language as well as all
470 symptom domains relevant to patients might explain a greater extent of the variation in severity
471 of biologic findings when compared to assessing dysphagia frequency alone.

472
473 The Pediatric Eosinophilic Esophagitis Symptom Score (PEESS v2.0) is the only currently
474 available instrument for assessing symptoms in pediatric patients with EoE. Although there are
475 data to convincingly demonstrate the alignment between patient-reported and proxy-reported
476 symptom severity, there are not enough data to understand the performance of this instrument
477 in the context of treatment response, especially given that: 1) there is a 30-day recall period for
478 this instrument; 2) age influences symptom presentation in children; and 3) a broad range of
479 symptoms need to be assessed.

480

481 **Conclusions**

482 In conclusion, we have developed an internationally guided multidisciplinary COS for use in
483 therapeutic trials in pediatric and adult patients with EoE. Groups assessing EoE therapies

484 should be encouraged to adopt this COS to reduce heterogeneity in outcome reporting and
485 improve comparability to future studies. We recognize that the endpoints used in EoE trials have
486 evolved rapidly over the past two decades. Indeed, limitations of existing instruments for
487 measuring histology, endoscopy, symptoms, and quality of life were highlighted during the
488 discussions that occurred in the consensus process and are reviewed in the accompanying
489 Meeting Summary. Therefore, while this is the first iteration of a COS in EoE, we anticipate that
490 ongoing work in the development of new instruments for measuring disease activity will shape
491 the field moving forwards. Importantly, the development of this COS represents only the
492 minimum outcomes that should be currently measured but should not discourage the
493 development and validation of potentially more robust or appropriate instruments to measure
494 disease activity in the future. In fact, we urge all investigators to measure other potential
495 outcomes of interest, in addition to these benchmarked minimum endpoints. Areas of research
496 priority, including comparisons of the performance characteristics of different tools for
497 measuring disease activity in diverse patient populations, will help to inform the next version of
498 this COS.

499 **References**

- 500 1. de Rooij WE, Dellon ES, Parker CE, et al. Pharmacotherapies for the Treatment of
501 Eosinophilic Esophagitis: State of the Art Review. *Drugs* 2019;79:1419-1434.
- 502 2. Lucendo AJ, Miehlke S, Schlag C, et al. Efficacy of Budesonide Orodispersible Tablets
503 as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled
504 Trial. *Gastroenterology* 2019;157:74-86 e15.
- 505 3. Straumann A, Lucendo AJ, Miehlke S, et al. Budesonide Orodispersible Tablets Maintain
506 Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic
507 Esophagitis. *Gastroenterology* 2020;159:1672-1685 e5.
- 508 4. Hirano I, Collins MH, Katzka DA, et al. Efficacy of Budesonide Oral Suspension for
509 Eosinophilic Esophagitis in Adolescents and Adults: Results From a Phase 3,
510 Randomized, Placebo-Controlled Trial. *Official journal of the American College of*
511 *Gastroenterology | ACG* 2019;114:S205-S206.
- 512 5. Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of Dupilumab in a Phase 2 Randomized
513 Trial of Adults With Active Eosinophilic Esophagitis. *Gastroenterology* 2020;158:111-122
514 e10.
- 515 6. Ma C, van Rhijn BD, Jairath V, et al. Heterogeneity in Clinical, Endoscopic, and
516 Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of
517 Eosinophilic Esophagitis: A Systematic Review. *Clin Gastroenterol Hepatol*
518 2018;16:1714-1729 e3.
- 519 7. Williamson PR, Altman DG, Bagley H, et al. The COMET Handbook: version 1.0. *Trials*
520 2017;18:280.
- 521 8. Kirkham JJ, Davis K, Altman DG, et al. Core Outcome Set-STAndards for Development:
522 The COS-STAD recommendations. *PLoS Med* 2017;14:e1002447.
- 523 9. Warners MJ, Hindryckx P, Levesque BG, et al. Systematic Review: Disease Activity
524 Indices in Eosinophilic Esophagitis. *Am J Gastroenterol* 2017;112:1658-1669.

- 525 10. Safroneeva E, Balsiger L, Hafner D, et al. Adults with eosinophilic oesophagitis identify
526 symptoms and quality of life as the most important outcomes. *Aliment Pharmacol Ther*
527 2018;48:1082-1090.
- 528 11. Tugwell P, Boers M, Brooks P, et al. OMERACT: an international initiative to improve
529 outcome measurement in rheumatology. *Trials* 2007;8:38.
- 530 12. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 2. Framing the question and
531 deciding on important outcomes. *J Clin Epidemiol* 2011;64:395-400.
- 532 13. Collins MH, Martin LJ, Alexander ES, et al. Newly developed and validated eosinophilic
533 esophagitis histology scoring system and evidence that it outperforms peak eosinophil
534 count for disease diagnosis and monitoring. *Dis Esophagus* 2017;30:1-8.
- 535 14. Dellon ES. Eosinophilic esophagitis: diagnostic tests and criteria. *Curr Opin*
536 *Gastroenterol* 2012;28:382-8.
- 537 15. Lyons E, Donohue K, Lee JJ. Developing Pharmacologic Treatments for Eosinophilic
538 Esophagitis: Draft Guidance from the United States Food and Drug Administration.
539 *Gastroenterology* 2019;157:275-277.
- 540 16. Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and
541 adults: a systematic review and consensus recommendations for diagnosis and
542 treatment. *Gastroenterology* 2007;133:1342-63.
- 543 17. Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated International Consensus
544 Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference.
545 *Gastroenterology* 2018;155:1022-1033 e10.
- 546 18. Dellon ES, Gonsalves N, Hirano I, et al. ACG clinical guideline: Evidenced based
547 approach to the diagnosis and management of esophageal eosinophilia and eosinophilic
548 esophagitis (EoE). *Am J Gastroenterol* 2013;108:679-92; quiz 693.

- 549 19. Hiremath G, Correa H, Acra S, et al. Correlation of endoscopic signs and mucosal
550 alterations in children with eosinophilic esophagitis. *Gastrointest Endosc* 2020;91:785-
551 794 e1.
- 552 20. Safroneeva E, Straumann A, Coslovsky M, et al. Symptoms Have Modest Accuracy in
553 Detecting Endoscopic and Histologic Remission in Adults With Eosinophilic Esophagitis.
554 *Gastroenterology* 2016;150:581-590 e4.
- 555 21. Hirano I, Moy N, Heckman MG, et al. Endoscopic assessment of the oesophageal
556 features of eosinophilic oesophagitis: validation of a novel classification and grading
557 system. *Gut* 2013;62:489-95.
- 558 22. Wechsler JB, Bolton SM, Amsden K, et al. Eosinophilic Esophagitis Reference Score
559 Accurately Identifies Disease Activity and Treatment Effects in Children. *Clin*
560 *Gastroenterol Hepatol* 2018;16:1056-1063.
- 561 23. Dellon ES, Katzka DA, Collins MH, et al. Budesonide Oral Suspension Improves
562 Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in
563 Patients With Eosinophilic Esophagitis. *Gastroenterology* 2017;152:776-786 e5.
- 564 24. Schoepfer AM, Straumann A, Panczak R, et al. Development and validation of a
565 symptom-based activity index for adults with eosinophilic esophagitis. *Gastroenterology*
566 2014;147:1255-66 e21.
- 567 25. Dellon ES, Irani AM, Hill MR, et al. Development and field testing of a novel patient-
568 reported outcome measure of dysphagia in patients with eosinophilic esophagitis.
569 *Aliment Pharmacol Ther* 2013;38:634-42.

570

571

572 **Tables and Figures Legend**

573

574 **Table 1.** Core outcome set for eosinophilic esophagitis

575 **Figure 1.** Outcome domains for inclusion in the eosinophilic esophagitis core outcome set

576

Journal Pre-proof

577 **Table 1.** Core outcome set for eosinophilic esophagitis

Outcome Domain	Randomized Controlled Trials	Observational Studies
Histopathology	<ul style="list-style-type: none"> □ Peak esophageal eosinophilia (and appropriate measures of spread, such as error terms or confidence intervals) should be measured and reported in all RCTs, expressed as: <ul style="list-style-type: none"> ▪ Number of eosinophils per high-power field (400 × magnification) ▪ Number of cells adjusted per mm² (400 × magnification) □ Histologic remission should be measured in all RCTs <ul style="list-style-type: none"> ▪ In RCTs, histologic remission should be defined based on a peak eosinophil count of < 15 esophageal eosinophils per high-power field in any location^a □ The grade (severity) and stage (extent) of all components in the EoE Histologic Scoring System (EoEHSS) should be measured and reported in all RCTs <ul style="list-style-type: none"> ▪ The EoEHSS remission score should be measured and reported in all RCTs: for each item, proximal and distal esophagus: remission score of ≤ 3 for grade AND ≤ 3 for stage AND peak eosinophil count of < 15 eos/hpf 	<ul style="list-style-type: none"> □ Peak esophageal eosinophilia (and appropriate measures of spread, such as error terms or confidence intervals) should be measured and reported in all observational studies, expressed as: <ul style="list-style-type: none"> ▪ Number of eosinophils per high-power field (400 × magnification) ▪ Number of cells adjusted per mm² (400 × magnification) □ Histologic remission should be measured in all observational studies <ul style="list-style-type: none"> ▪ In observational studies, histologic remission should be defined based on a peak eosinophil count of < 15 esophageal eosinophils per high-power field in any location
	Endoscopy	<ul style="list-style-type: none"> □ The Endoscopic Reference Score (EREFS) should be measured and reported in all RCTs <ul style="list-style-type: none"> ▪ The major features of the EREFS should be scored from 0 to 8, scoring the most severe grade of esophageal EoE-associated features present in the proximal and distal esophagus (with furrows scored as absent or present)^b
<ul style="list-style-type: none"> □ Endoscopic remission based on EREFS should be measured and reported in all RCTs and observational studies <ul style="list-style-type: none"> ▪ In RCTs or observational studies, the endoscopic EREFS-based remission should be defined as an EREFS score ≤ 2 (based on EREFS scoring from 0 to 8)^b ▪ In RCTs or observational studies, endoscopic inflammatory EREFS-based remission should be defined as the inflammation-associated components (exudate, edema, furrows) score ≤ 2 (based on EREFS scoring from 0 to 8)^c ▪ In RCTs or observational studies, the endoscopic fibrotic EREFS-based remission should be defined as categorical definition as absence of strictures, moderate and severe rings 		

Outcome Domain	Randomized Controlled Trials	Observational Studies
Patient-Reported Symptoms	<ul style="list-style-type: none"> □ In all RCTs, symptom severity in adults with EoE should be assessed using a generic instrument with a daily recall period^d □ In all RCTs, symptom severity in adults with EoE should be assessed using the following instruments: <ul style="list-style-type: none"> ▪ Dysphagia Symptom Questionnaire ▪ Eosinophilic Esophagitis Activity Index (7-day recall period) □ In all RCTs, the following language should be used to query dysphagia in adults with EoE: <ul style="list-style-type: none"> ▪ Dysphagia defined as trouble swallowing ▪ Dysphagia defined as delayed or slow passage of food □ In all RCTs, symptom severity in pediatric EoE patients should be measured using Pediatric Eosinophilic Esophagitis Symptom Score (PEESS v2.0) 	<p>No patient-reported symptom instruments met consensus thresholds for use in all observational studies</p> <ul style="list-style-type: none"> □ In all observational studies, the following language should be used to query dysphagia in adults with EoE: <ul style="list-style-type: none"> ▪ Dysphagia defined as trouble swallowing ▪ Dysphagia defined as delayed or slow passage of food
Quality of Life	<ul style="list-style-type: none"> □ In all RCTs, EoE-specific quality of life in adults should be measured using EoE Quality of Life (EoE-QoL-A) questionnaire □ In all RCTs, pediatric EoE-specific quality of life should be measured using The Pediatric Quality of Life Inventory (PedsQL) EoE Module <ul style="list-style-type: none"> ▪ When using PedsQL EoE Module for children, for whom both parent-proxy report and child self-report are available, both should be reported in all RCTs 	<p>No patient-reported quality of life instruments met consensus thresholds for use in all observational studies</p>

578

579 ^a Remission cut-off of <15 eosinophils/hpf corresponding to <60 eosinophils/mm²

580 ^b See text (COS: Endoscopy Outcomes) for full details; if the EREFS is scored from 0 to 9 with furrows graded as
 581 grade 0 (absent), grade 1 (mild, vertical lines without visible depth), and grade 2 (severe, vertical lines with mucosal
 582 depth), recommended to report component scores to calculate post-hoc an EREFS score on a 0 to 8 scale

583 ^c Endoscopic remission recommended to be defined by EREFS≤2 if scored on 0 to 8, or 0 to 9 scale

584 ^d See text (COS: Patient-Reported Symptoms) for full details; considered appropriate to use a generic instrument with
 585 a daily recall period in accordance with regulatory recommendations

586 Abbreviations: EoE eosinophilic esophagitis; EoEHSS EoE Histologic Scoring System; EoE-QoL-A, EoE Quality of
 587 Life for adults, EREFS Endoscopic Reference Score; hpf high power field; PedsQL Pediatric Quality of Life Inventory;
 588 PEES Pediatric EoE Symptom Score; RCT randomized controlled trial

Research agenda domains

- Secondary impact on family/caregivers
- Resource utilization

Important domains but optional

- Genetic profiling
- Biomarkers
- Esophageal distensibility
- Immunologic dissection
- Patient perception of health

Critical for inclusion (core domains)

- Histopathology
- Endoscopy
- Patient-reported symptoms
- EoE-specific QoL

Journal Pre-proof